艾拉索米瑞(Elasomeran) - 药物靶点：SARS-CoV-2 S protein_在研适应症：新型冠状病毒“奥密克戎”变异株感染，新型冠状病毒感染，流感病毒感染_专利_临床

概要

基本信息

药物类型

预防性疫苗、mRNA疫苗

别名

andusomeran、COVID-19 mRNA vaccine、COVID-19 Vaccine Moderna

+ [12]

靶点

SARS-CoV-2 S protein

作用方式

抑制剂

作用机制

SARS-CoV-2 S protein抑制剂(冠状病毒刺突糖蛋白抑制剂)

治疗领域

感染呼吸系统疾病其他疾病

在研适应症

新型冠状病毒“奥密克戎”变异株感染新型冠状病毒感染流感病毒感染+ [3]

非在研适应症

免疫抑制肺移植排斥反应

原研机构

Moderna, Inc.

在研机构

ModernaTX, Inc.

Moderna, Inc.Moderna Biotech Spain, S.L.

+ [2]

非在研机构

Takeda Pharmaceutical Co., Ltd.

权益机构

Takeda Pharmaceutical Co., Ltd.

Tabuk Pharmaceuticals Manufacturing Co.

Medison Pharma Ltd.

+ [5]

最高研发阶段批准上市

首次获批日期

加拿大 (2020-12-23),

新型冠状病毒感染

最高研发阶段(中国)-

特殊审评优先审评 (美国)、快速通道 (美国)、紧急使用授权 (美国)

登录后查看时间轴

结构/序列

Sequence Code 776927365

来源: *****

关联

74

项与艾拉索米瑞相关的临床试验

NCT06585241

/ Active, not recruiting临床4期

A Phase 3b/4, Open-label Study to Assess the Immunogenicity of mRNA COVID-19 Variant-containing Vaccine Formulations in Previously Vaccinated Adults Aged ≥18 Years

The purpose of this study is to investigate the immunogenicity of mRNA COVID-19 variant-containing vaccine formulations against the vaccine matched variants and newly emerged variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in previously vaccinated adults.

开始日期2024-09-09

申办/合作机构

ModernaTX, Inc.

NCT05387317

/ Withdrawn临床3期

A Randomised Controlled Trial to Assess the Immunogenicity, Safety & Reactogenicity of Standard Dose Versus Fractional Doses of COVID-19 Vaccines (Pfizer-BioNTech, AstraZeneca or Moderna) Given as a Booster Dose After Priming With Coronavac or AstraZeneca in Healthy Adults in Indonesia

This is a randomised controlled clinical trial to determine the reactogenicity and immunogenicity of booster doses of SARS-CoV-2 vaccines (Pfizer-BioNTech, AstraZeneca or Moderna) in adults who have previously received either AstraZeneca or Coronavac as their primary doses.
Both fractional and standard doses of Pfizer-BioNTech, AstraZeneca and Moderna will be tested.

开始日期2024-04-01

申办/合作机构

Murdoch Childrens Research Institute

[+4]

PACTR202212801139469

/ Unknown status临床2期

A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled, Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to < 18 years of age

开始日期2023-08-01

申办/合作机构-

100 项与艾拉索米瑞相关的临床结果

登录后查看更多信息

100 项与艾拉索米瑞相关的转化医学

登录后查看更多信息

100 项与艾拉索米瑞相关的专利（医药）

登录后查看更多信息

2,523

项与艾拉索米瑞相关的文献（医药）

2025-12-31·Human Vaccines & Immunotherapeutics

Safety and immunogenicity of an mRNA-1273 vaccine booster in adolescents

Article

作者: Powell, Richard ; Boone, Gary ; Ali, Kashif ; Etokhana, Kenneth ; Clifford, Robert ; Figueroa, Amparo L. ; Miller, Jacqueline ; Rizzardi, Barbara ; Ampajwala, Madhavi ; Girard, Bethany ; Weiner, Leonard ; Slobod, Karen ; Kirstein, Judith ; Yeakey, Anne ; Carr, Quito ; Segall, Nathan ; Fierro, Carlos ; Elfaki, Salma ; Akinsola, Adebayo ; Xu, Wenqin ; Berman, Gary ; Ohnmacht, Richard ; Chu, Laurence ; Reyes-Acuna, Celia ; Turner, Mark ; Buynak, Robert ; Ruiz-de-Luzuriaga, Katherine ; Matherne, Paul ; Jeanfreau, Robert ; Priddy, Frances ; Das, Rituparna ; Deng, Weiping ; Griffin, Carl ; Adetona, Olutola

Safety, immunogenicity, and effectiveness of an mRNA-1273 50-μg booster were evaluated in adolescents (12-17 years), with and without pre-booster SARS-CoV-2 infection. Participants who had received the 2-dose mRNA-1273 100-µg primary series in the TeenCOVE trial (NCT04649151) were offered the mRNA-1273 50-μg booster. Primary objectives included safety and inference of effectiveness by establishing noninferiority of neutralizing antibody (nAb) responses after the booster compared with the nAb post-primary series of mRNA-1273 among young adults in COVE (NCT04470427). Binding antibody (bAb) responses against SARS-CoV-2 variants of interest and COVID-19 incidence after vaccination were also evaluated. Median boosting interval was 315 days. The mRNA-1273 booster was well-tolerated, with an acceptable safety profile. Relative to pre-booster, nAb geometric mean levels increased after the booster by 17.8-fold and 4.7-fold among pre-booster SARS-CoV-2-negative and -positive participants, respectively. Effectiveness was successfully inferred based on noninferiority of nAb levels from mRNA-1273 booster dose (Day 29) compared with nAb levels after mRNA-1273 primary series (Day 57) among young adults in COVE. Further, the booster increased bAb levels relative to pre-booster baseline against SARS-CoV-2 variants (alpha [B.1.1.7], beta [B.1.351], gamma [P.1], and delta [B.1.617.2]), regardless of pre-booster SARS-CoV-2 status. COVID-19 incidence (cases per 1000 person-months) was lower among boosted (0 cases) than non-boosted (95.766 cases) participants in January 2022, a peak period during the early omicron transmission. In summary, the mRNA-1273 50-μg booster induced robust nAb responses in previously vaccinated adolescents, regardless of SARS-CoV-2 serostatus. Effectiveness was successfully inferred and the booster was well-tolerated, with no new safety concerns identified.

2025-12-31·ANNALS OF MEDICINE

Neutralizing antibodies against SARS-CoV-2 of vaccinated healthcare workers in Taiwan

Article

作者: Syu, Guan-Da ; Kuo, Kuang-Che ; Weng, Ken-Pen ; Kuo, Ho-Chang ; Priyambodo, Seto ; Liu, Shih-Feng

BACKGROUND:

Vaccination is one of the best ways to control the SARS-CoV-2 outbreak. In Taiwan, healthcare workers were prioritized for vaccination, but the effectiveness of these vaccines for them remains unclear. Thus, it's essential to examine their neutralizing antibodies after prime-boost vaccinations.

METHODS:

In this prospective observational study, 514 healthcare workers from Chang Gung Memorial hospitals in Taiwan were included between 19 March 2021 and 21 August 2021. The two doses of COVID-19 vaccines were either a match or a mixing of AZD1222 and mRNA-1273, e.g. AZD1222 + AZD1222 (n = 406), mRNA-1273 + mRNA-1273 (n = 62), and AZD1222 + mRNA-1273 (n = 46). Blood specimens were drawn after two doses of vaccines, defined as post-vaccine days [median 34.00 days and interquartile range (IQR) 29.00-42.00 days], and examined for the neutralizing antibodies via SARS-CoV-2 neutralization kits. The results were analyzed as a percentage of inhibition based on the negative control.

RESULTS:

After 2 vaccination doses, subjects with AZD1222 + mRNA-1273 (median 97.15%, IQR 96.06-98.06%) and mRNA-1273 + mRNA-1273 (median 97.47%, IQR 96.75-97.89%) exhibited higher neutralizing antibodies than those receiving AZD1222 + AZD1222 vaccines (median 71.28%, IQR 49.39-89.70%) (the percentage was referred to inhibition of surrogate virus). The post-vaccination days negatively impacted the neutralizing antibodies, except for the mRNA-1273 + mRNA-1273 group. The presence of fever, headache, and myalgia after the second dosage was reflected in the higher neutralizing antibodies (median of no fever 76.00% vs. fever 97.00%, p < 0.0001; median of no headache 76.00% vs. headache 95.00%, p < 0.0001; median of no myalgia 75.50% vs. myalgia 96.00%, p < 0.0001). The subjects with underlying diseases, including hypertension and cancer showed lower neutralizing antibodies (median of no hypertension 81.00% vs. hypertension 56.00%, p = 0.0029; median of no cancer 81.00% vs. cancer 56.00%, p = 0.0143).

CONCLUSION:

Heterologous prime-boost vaccines (AZD1222 + mRNA-1273) and two doses of mRNA vaccines are recommended. For future directions, we need to investigate the effectiveness of the vaccination against new SARS-CoV-2 variants.

2025-12-01·IMMUNOLOGIC RESEARCH

QuantiFERON SARS-CoV-2 assay for the evaluation of cellular immunity after immunization with mRNA SARS-CoV-2 vaccines: a systematic review and meta-analysis

Review

作者: Michos, Athanasios ; Kourlaba, Georgia ; Dourdouna, Maria-Myrto

A systematic review and meta-analysis were performed to evaluate the virus-specific T-cell response after COVID-19 mRNA vaccination, using the QuantiFERON SARS-CoV-2 interferon-γ release assay. A search was conducted (June 8, 2023) in the PUBMED, SCOPUS, and medRxiv databases, to identify studies reporting the QuantiFERON SARS-CoV-2 (Starter (two antigen tubes) or Starter + Extended Pack (three antigen tubes), cut-off ≥ 0.15 IU/mL) positivity rate (PR) in immunocompetent adults, following the administration of two or three COVID-19 mRNA vaccine doses. Study quality was evaluated with the Critical Appraisal Skills Programme Tool. A meta-analysis was conducted using a random-effects model. Heterogeneity and publication bias were assessed. Eleven eligible studies (with 5-73 vaccinated immunocompetent participants) were identified. For COVID-19-naïve participants, ≤ 3 months after the second dose, the pooled PR (random-effects model) was 86 (95% confidence interval (95% CI) 78-95%). Comparing the Starter vs. the Starter + Extended Pack, a significant difference in PRs was detected (80.6% vs. 100% p-value < 0.001). At 3-6 and >6 months after the second dose and ≥ 3 months after the third dose, the pooled PRs were 59% (95% CI 45-72%), 79% (95% CI 66-92%), and 66% (95% CI 50-82%), respectively. For convalescent participants, ≥ 6 months after the third dose, the pooled PR was 81% (95% CI 67-95%). Limitations include heterogeneity and a small number of studies, at some timepoints. In conclusion, following the second or third COVID-19 mRNA vaccine dose, QuantiFERON SARS-CoV-2 detected positive responses in a certain percentage of the vaccinees, possibly because of waning immunity, reduced assay sensitivity, or lack of T-cell response induction in some vaccinees. The detection of positive responses was higher when the Starter + Extended Pack was used. PROSPERO Registration Number: CRD42023431315.

1,197

项与艾拉索米瑞相关的新闻（医药）

2025-08-01

·BioSpace

Moderna Wins UK Patent Battle Against Pfizer and BioNTech

iStock, hapabapa A U.K. Court of Appeals ruling confirms the validity of a patent covering modifications of mRNA used in Moderna’s vaccines. The U.K. Court of Appeals has ruled in Moderna’s favor in a patent dispute between the vaccine maker and its chief competitor, Pfizer and its partner BioNTech. The decision confirms a ruling dating to July 2024 that Moderna’s EP’949 patent is valid, and that Pfizer/BioNTech’s Comirnaty COVID-19 vaccine infringes upon it. Moderna announced the ruling in a press release early Friday morning and confirmed it during the company’s second-quarter earnings call hours later. “You may have seen that in the last couple of hours, the U.K. Court of Appeal issued its decision,” Moderna’s CEO Stéphane Bancel said on the call. “The court has decided to affirm the High Court finding that Moderna’s EP’949 patent is valid and infringed by Pfizer and BioNTech. Moderna will continue to pursue and enforce its patent rights globally to protect its competitive mRNA technology.” The EP’949 patent covers modifications made to the mRNA used in COVID-19 vaccines. That modification replaces the uracil bases in mRNA with N1-methyl-pseudouridine, a modified version of the base that stabilizes the molecule and stimulates a strong immune response. Early in the COVID-19 pandemic, in October 2020 , Moderna said that it would not enforce its COVID-19–related patents. But in March 2022, the biotech updated this pledge , saying it would enforce its patents except in 92 low- or middle-income countries. The U.K. case dates back to August 2022 , when Moderna sued Pfizer and BioNTech in the U.S. and Germany (where BioNTech is based), as well as the Netherlands, Belgium and Ireland, for infringement of the EP’949 patent. Moderna’s complaint said it was entitled to damages relating to sales dating back to March 2022. In September 2022, Pfizer shot back in U.K. courts, asking for the patent to be revoked there, insisting that its own patents had been infringed. In July 2024, an initial ruling came down in the U.K. that declared one of Moderna’s patents, EP’565 , which covered a “betacoronavirus mRNA-LNP vaccine” invalid. However, it said that EP’949, the patent on modified uracils, was valid. The court gave Pfizer the option to appeal the decision, which it did. The cases across various countries have come to varied conclusions. In March, the Düsseldorf Regional Court ruled that Moderna’s patents were valid and ordered Pfizer and BioNTech to pay damages. A few weeks later, the U.S. Patent Trial and Appeal Board ruled that three other Moderna patents around mRNA technology attempted to patent “obvious” advances and were therefore invalid.

疫苗专利侵权信使RNA

2025-07-31

·PipelineReview

Moderna Receives European Commission Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1

CAMBRIDGE, MA, USA I July 30, 2025 I Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission (EC) has granted marketing authorization for the updated formulation of the COVID-19 vaccine Spikevax®, targeting the SARS-CoV-2 variant LP.8.1, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals six months of age and older. This marketing authorization follows the Positive Opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). The authorization is valid in all 27 EU member states, as well as Iceland, Liechtenstein and Norway. Following the EC decision, doses will be available for eligible populations ahead of the 2025-2026 vaccination season. “We appreciate the EC’s timely review and are pleased that our updated COVID-19 vaccine will be available to protect the public against currently circulating strains,” said Stéphane Bancel, Chief Executive Officer of Moderna. “COVID-19 continues to impact individuals and healthcare systems globally and we encourage people to speak to their healthcare providers about receiving an updated vaccine.” The marketing authorization follows guidance from various global health authorities, which recommended that COVID-19 vaccines be updated to target the LP.8.1 strain for the 2025-2026 vaccination season. Moderna’s COVID-19 vaccines have been generally well-tolerated. The most common solicited local adverse event for Moderna’s COVID-19 vaccines is injection site pain. The most common solicited systemic adverse events include headache, fatigue, myalgia and chills. Additional regulatory applications for Moderna’s updated COVID-19 vaccines targeting LP.8.1 are under review around the world. About Moderna Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. Moderna’s mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. SOURCE: Moderna Therapeutics

疫苗上市批准信使RNA紧急使用授权

2025-07-31

·Firstwordpharma

EU okays Moderna’s updated COVID-19 jab for upcoming season

The European Commission (EC) approved an updated version of Moderna’s COVID-19 vaccine Spikevax — targeting the SARS-CoV-2 variant LP.8.1 — designed to offer enhanced protection against current strains. The clearance — which succeeds a recent positive opinion adopted by the EU drug advisory body — enables active immunisation against COVID-19 for eligible individuals aged six months and older, ahead of the 2025-2026 vaccination season. The vaccine’s current iteration follows the recommendation of the European Medicine Agency’s Emergency Task Force to target the LP.8.1 variant, aiming to maintain vaccine effectiveness amid ongoing viral evolution. "We appreciate the EC's timely review and are pleased that our updated COVID-19 vaccine will be available to protect the public against currently circulating strains," said Stéphane Bancel, chief executive of Moderna. Earlier this month, the FDA converted Spikevax’s emergency use authorisation to full approval for children aged 6 months to 11 years. In May, the US regulator also greenlit Moderna's next-gen COVID-19 vaccine, mNEXSPIKE (mRNA-1283), but limited its use to adults aged 65 and above and high-risk individuals ages 12 to 64.

疫苗上市批准信使RNA紧急使用授权

100 项与艾拉索米瑞相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	艾拉索米瑞	J07	DB15654

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
新型冠状病毒“奥密克戎”变异株感染	英国	Moderna, Inc.	2022-08-15
新型冠状病毒感染	加拿大	Moderna, Inc.	2020-12-23

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
严重急性呼吸综合征	临床2期	美国	ModernaTX, Inc.	2022-09-30
流感病毒感染	临床2期	美国	ModernaTX, Inc.	2022-05-13
免疫抑制	临床2期	美国	ModernaTX, Inc.	2022-03-10
肺移植排斥反应	临床2期	美国	ModernaTX, Inc.	2022-03-10
巨细胞病毒感染	临床1期	美国	ModernaTX, Inc.	2022-05-24
呼吸道合胞体病毒感染	临床1期	美国	ModernaTX, Inc.	2022-05-24

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05160766 (EU-COVAT-1 \| EU-COVAT-1_AGED, CTgov)	临床2期	新型冠状病毒感染	323	Comirnaty (BNT162b2 (Part A))	蓋壓淵衊選廠築簾願餘 = 蓋製範廠夢築餘鹽齋獵淵壓餘憲壓繭齋憲顧構 (鹹醖觸繭選餘範艱糧積, 簾鹽願餘選襯鏇獵廠簾 ~ 鬱餘繭遞製築顧糧醖構) 更多	-	2025-05-20
				Spikevax (mRNA-1273 (Part A))	蓋壓淵衊選廠築簾願餘 = 選廠蓋網廠夢選膚築鹹淵壓餘憲壓繭齋憲顧構 (鹹醖觸繭選餘範艱糧積, 選築鏇簾鹽願選窪獵鹽 ~ 衊鏇鬱廠遞淵範簾膚網) 更多
NCT05280158 (CTgov)	临床1/2期	肺移植排斥反应 \| 免疫抑制	19	mRNA-1273 (Moderna COVID-19 vaccine) (Standard-dose)	鹽遞獵鬱願築膚衊鏇獵 = 鹹夢壓夢選衊簾憲範製膚簾淵鹹顧製遞簾憲夢 (範繭範鹹夢醖膚選繭製, 糧廠齋簾選鏇壓築選蓋 ~ 餘醖憲積範夢夢窪顧齋) 更多	-	2025-03-26
				mRNA-1273 (Moderna COVID-19 vaccine) (Mid-Dose)	鹽遞獵鬱願築膚衊鏇獵 = 積廠壓觸襯鑰膚淵艱鑰膚簾淵鹹顧製遞簾憲夢 (範繭範鹹夢醖膚選繭製, 淵鹽繭廠艱餘壓繭憲繭 ~ 齋鏇網鹽鏇夢鹹選製窪) 更多
NCT05022329 (BOOST KIDNEY, CTgov)	临床2/3期	新型冠状病毒感染 \| 慢性肾病，V期 \| 慢性肾病	273	BNT162b2 (Third Dose BNT162b2)	繭積獵夢範窪膚齋鬱鏇(壓糧衊範淵遞壓憲夢觸) = 醖壓鏇鹽製範簾鑰壓願壓鏇餘艱範淵繭鑰夢齋 (構醖襯齋夢鬱餘鏇獵淵, 0.334) 更多	-	2025-02-19
				mRNA-1273 (Moderna) (Third Dose mRNA-1273)	繭積獵夢範窪膚齋鬱鏇(壓糧衊範淵遞壓憲夢觸) = 艱夢膚鑰膚顧構蓋簾顧壓鏇餘艱範淵繭鑰夢齋 (構醖襯齋夢鬱餘鏇獵淵, 0.169) 更多
NCT05047770 (Pubmed) 人工标引	临床3期	带状疱疹	497	mRNA-1273quFlu D-QIVt influenza vaccine (QIV)	齋憲醖膚襯廠遞鏇齋簾(齋顧蓋築鏇遞蓋顧襯廠) = The most frequently reported adverse events in both groups were pain at the injection site and myalgia. 壓衊艱築構夢齋鹹鑰顧 (鹽鏇餘願鏇鹹網製製構 ) 更多	非劣	2024-12-31
				mRNA-1273 + Flu D-QIV(CoAd )
NCT05228730 (MIACoV, CTgov)	临床3期	新型冠状病毒感染	13	Tozinameran (Standard Pfizer-BioNTech Booster Group)	遞遞餘構願淵廠鬱壓獵(製顧襯憲簾壓選糧鬱衊) = 憲醖艱製鬱簾鹹構選淵艱構願繭夢窪築膚遞鑰 (糧蓋構夢淵壓壓簾餘簾, 製鹹淵觸襯鏇餘製鹽鏇 ~ 製壓窪簾遞鬱鏇簾製觸) 更多	-	2024-12-16
				Tozinameran - fractional dose (Fractional Pfizer-BioNTech Booster Group)	遞遞餘構願淵廠鬱壓獵(製顧襯憲簾壓選糧鬱衊) = 鹹構顧獵獵願餘鹹簾糧艱構願繭夢窪築膚遞鑰 (糧蓋構夢淵壓壓簾餘簾, 鬱網餘鬱願選艱齋餘窪 ~ 願繭襯衊積艱廠餘壓鑰) 更多
NCT05249829 (CTgov)	临床2/3期	新型冠状病毒感染	3,548	mRNA-1273.529 (Part 1: mRNA-1273.529)	窪窪齋衊製淵範夢鹽糧(網網夢醖顧積築鏇網壓) = 淵願顧廠憲鹹網獵鹽艱遞觸膚夢鏇廠鏇衊鹹範 (鑰選簾醖顧遞膚蓋築糧, 衊壓鬱觸廠齋繭艱繭積 ~ 鏇遞衊簾壓糧鹹構膚構) 更多	-	2024-08-09
				mRNA-1273 (Part 1: mRNA-1273)	窪窪齋衊製淵範夢鹽糧(網網夢醖顧積築鏇網壓) = 鹹築遞夢網夢鬱淵窪繭遞觸膚夢鏇廠鏇衊鹹範 (鑰選簾醖顧遞膚蓋築糧, 餘蓋鹹衊獵餘範鹹艱鏇 ~ 蓋蓋襯糧窪簾繭艱壓淵) 更多
NCT05375838 (CTgov)	临床1/2期	新型冠状病毒感染 \| 流感病毒感染	550	placebo+mRNA-1273 (mRNA-1273 + Placebo)	簾鏇壓簾衊鹽壓繭醖觸 = 網願網獵廠鏇艱衊獵壓鹽憲繭鹽鏇齋鏇網壓衊 (觸廠糧餘製遞範願築積, 餘繭遞鏇憲艱夢獵構鹽 ~ 築窪糧醖醖鏇壓淵簾衊) 更多	-	2024-02-28
				placebo+mRNA-1010 (mRNA-1010 + Placebo)	簾鏇壓簾衊鹽壓繭醖觸 = 選願鏇構糧襯齋製選製鹽憲繭鹽鏇齋鏇網壓衊 (觸廠糧餘製遞範願築積, 構鏇構構襯願製窪壓遞 ~ 構製鏇顧顧顧鑰憲齋窪) 更多
DDW2023	N/A	炎症性肠病	-	BNT162b2 (Pfizer)	膚齋鬱鬱醖顧鬱襯淵築(窪鬱餘鬱鑰積夢積鑰繭) = 顧齋糧構憲顧廠膚網衊廠遞窪積夢網範膚範繭 (壓廠願夢膚壓壓獵衊淵 ) 更多	-	2023-05-07
NCT04677660 (CTgov)	临床1/2期	新型冠状病毒感染	200	Placebo	壓簾鏇構憲遞網觸醖廠 = 夢醖繭鹽齋襯膚選顧築壓蓋鬱艱壓夢製網觸餘 (餘蓋齋膚淵鹹淵範願淵, 鬱鏇選鑰蓋簾夢獵簾顧 ~ 淵衊鑰築衊顧顧網膚簾) 更多	-	2023-05-03